Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03289962
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- NCT03289962 ↗
- Completed
- Genentech, Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03289962 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03289962 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Melanoma; Non-Small Cell Lung Cancer; Bladder Cancer; Colorectal Cancer; Triple Negative Breast Cancer; Renal Cancer; Head and Neck Cancer; Other Solid Cancers
- Interventions
- Autogene cevumeran; Atezolizumab
- Arms
- Phase 1a Flat Dose Escalation: Autogene Cevumeran · Experimental
- Phase 1b Flat Dose Escalation: Autogene Cevumeran + Atezolizumab · Experimental
- Phase Ib: Dose Exploration: Autogene Cevumeran + Atezolizumab · Experimental
- Phase 1b Expansion: Autogene Cevumeran + Atezolizumab · Experimental
- Phase 1b Expansion: Autogene Cevumeran + Atezolizumab (Serial Biopsy) · Experimental
- Enrollment
- 273
- Primary outcomes
- Percentage of Participants with Dose-Limiting Toxicities (DLTs)
- MTD/Recommended Phase 2 Dose (RP2D) of Autogene Cevumeran
- Percentage of Participants with Adverse Events (AEs)
- Percentage of Participants with Immune-Mediated Adverse Events (imAEs)
- Percentage of Participants by Number of Treatment Cycles Received
- Dose Intensity of Autogene Cevumeran
- Change from Baseline in Targeted Vital Signs
- Change from Baseline in Targeted Clinical Laboratory Test Results
- Change from Baseline in ECGs
- Sponsor
- Genentech, Inc. with BioNTech SE
- Start
- Dec 21, 2017
- Primary completion
- Jul 1, 2025
- Results posted
- No
- Registry record
- NCT03289962 · updated Jun 8, 2026
Publications
linked from the registry- Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher GA, Schmidt M, Schuler M, Sullivan RJ, Burris HA, Galvao V, Henick BS, Dirix L, Jaeger D, Ott PA, Wong KM, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner RS, Rittmeyer A, Laurie SA, Gort E, Aljumaily R, Melero I, Sabado RL, Rhee I, Mancuso MR, Muller L, Fine GD, Yadav M, Kim L, Leveque VJP, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao GK, Low DW, Petry C, Lo AA, Schartner JM, Delamarre L, Mellman I, Lower M, Muller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, Lorks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kroner C, Tadmor AD, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn AN, Sahin U, Tureci O, Camidge DR. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med. 2025 Jan;31(1):152-164. doi: 10.1038/s41591-024-03334-7. Epub 2025 Jan 6. PubMed 39762422